Evidence map›Paper›PMID 33614286›Full record

ArticlePeerJ2021

Prognostic implications of cell division cycle protein 45 expression in hepatocellular carcinoma.

Chen Yang, Shufang Xie, Yi Wu, Guoqing Ru, Xianglei He, Hong-Yin Pan, Shibing Wang, Xiangmin Tong

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Chen Yang *Department of Clinical Medicine, Qingdao University, Qingdao, China.
Shufang Xie *Molecular Diagnosis Laboratory, Zhejiang Provincial People's Hospital, Hangzhou, China.
Yi WuPhase I Clinical Research Center, Zhejiang Provincial People's Hospital, Hangzhou, China.
Guoqing RuDepartment of Pathology, Zhejiang Provincial People's Hospital, Hangzhou, China.
Xianglei HeDepartment of Pathology, Zhejiang Provincial People's Hospital, Hangzhou, China.
Hong-Yin PanDepartment of Infectious Diseases, Zhejiang Provincial People's Hospital, Hangzhou, China.
Shibing WangMolecular Diagnosis Laboratory, Zhejiang Provincial People's Hospital, Hangzhou, China.
Xiangmin TongMolecular Diagnosis Laboratory, Zhejiang Provincial People's Hospital, Hangzhou, China.
Zhejiang Provincial People's Hospital · CNQingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe overall prognosis of hepatocellular carcinoma (HCC) is poor and novel prognostic biomarkers might better monitor the progression of HCC. Cell division cycle protein 45 (CDC45) plays a key role in DNA replication and considered to be involved in tumorigenesis. This study investigated CDC45 expression in tumour tissues and defined its prognostic value in HCC patients.

methodsWe used immunohistochemistry (IHC) staining to examine the expression of CDC45 in tumour tissue specimens and compare them with adjacent normal tissue specimens using a constructed tissue microarray (TMA) and analyzed how clinical features are related to HCC prognosis. Functional enrichment analyses were used to describe significantly involved hallmark pathways of differentially expressed genes (DEGs, which were screened out according to the high or low expression of CDC45 in tumour tissues).

resultsOur findings showed that the proteome expression of CDC45 was evidently downregulated in HCC tissues compared with matched normal tissues ( DISCUSSION: Our findings showed that low proteomic level of CDC45 was associated with a poor prognosis in HCC patients, indicating that CDC45 might be a novel prognostic marker.

Indexed as

BioinformaticsBiomarkerCell division cycle protein 45Hepatocellular carcinoma

Identifiers

PMID33614286
PMCPMC7883691
OpenAlexW3131581506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.